Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions

Heart Transplant

Interventions

DRUG

Everolimus

Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit

DRUG

Mycophenolate mofetil Tablet/Capsule

Up to 1.5g BID(total 3g daily), PO

Trial Locations (1)

Samsung Medical Center, Seoul